Considerations on the efficacy and toxicity of neoadjuvant chemotherapy for BRPC.
作者信息
Fu Yuanzhi, Chen Junhao, Fu Shi
机构信息
Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Yunnan, China.
Kunming University of Science and Technology, Kunming, China.
出版信息
Int J Surg. 2025 Jun 1;111(6):4145-4146. doi: 10.1097/JS9.0000000000002428. Epub 2025 Apr 29.
Abstract
摘要
相似文献
1
Considerations on the efficacy and toxicity of neoadjuvant chemotherapy for BRPC.关于新辅助化疗对胆管周围癌疗效和毒性的考量
Int J Surg. 2025 Jun 1;111(6):4145-4146. doi: 10.1097/JS9.0000000000002428. Epub 2025 Apr 29.
2
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol.吉西他滨联合白蛋白结合型紫杉醇方案新辅助化疗治疗合并动脉侵犯的可切除边缘胰腺癌：一项前瞻性多中心单臂II期研究方案
Int J Surg Protoc. 2021 Apr 26;25(1):55-60. doi: 10.29337/ijsp.142.
3
Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.比较不同新辅助治疗方案对可切除及临界可切除胰腺癌的疗效和安全性：一项系统评价和网状Meta分析
Eur J Clin Pharmacol. 2023 Mar;79(3):323-340. doi: 10.1007/s00228-022-03441-9. Epub 2022 Dec 28.
4
Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma.局部进展期胰导管腺癌新辅助化疗后手术的临床疗效。
Cancer Res Treat. 2024 Oct;56(4):1240-1251. doi: 10.4143/crt.2023.977. Epub 2024 Jun 19.
5
Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.诱导化疗联合新辅助立体定向体部放疗治疗可切除边缘和局部晚期胰腺腺癌的长期疗效
Acta Oncol. 2015 Jul;54(7):979-85. doi: 10.3109/0284186X.2015.1004367. Epub 2015 Mar 3.
6
Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.当代新辅助化疗时代边缘可切除胰腺癌患者的结局。
J Gastrointest Surg. 2019 Jan;23(1):112-121. doi: 10.1007/s11605-018-3966-8. Epub 2018 Sep 21.
7
A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.吉西他滨/白蛋白紫杉醇/S-1 联合新辅助化疗治疗伴动脉侵犯的局部可切除胰腺癌的 II 期研究。
Eur J Cancer. 2021 Dec;159:215-223. doi: 10.1016/j.ejca.2021.10.012. Epub 2021 Nov 12.
8
A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement.吉西他滨联合白蛋白结合型紫杉醇新辅助化疗用于伴有动脉侵犯的可切除边缘胰腺癌的前瞻性多中心II期试验。
Ann Surg Oncol. 2023 Jan;30(1):193-202. doi: 10.1245/s10434-022-12566-1. Epub 2022 Oct 7.
9
Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.吉西他滨联合S-1新辅助化疗有助于提高小的临界可切除胰腺癌患者的生存率。
Surg Today. 2016 Nov;46(11):1282-9. doi: 10.1007/s00595-016-1310-z. Epub 2016 Feb 9.
10
Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.新辅助 FOLFIRINOX 方案治疗局部进展期和可切除边界胰腺癌：意向治疗分析。
Eur J Surg Oncol. 2018 Oct;44(10):1619-1623. doi: 10.1016/j.ejso.2018.07.057. Epub 2018 Aug 2.
本文引用的文献
1
Clinical efficacy and chemoresistance analysis of precision neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a prospective, single-arm pilot study.可切除边缘胰腺癌精准新辅助化疗的临床疗效与化疗耐药性分析：一项前瞻性单臂试点研究
Int J Surg. 2025 May 1;111(5):3269-3280. doi: 10.1097/JS9.0000000000002342.
Zotero 插件